Connor, Clark & Lunn Investment Management (CC&L)’s Integra LifeSciences IART Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-56,327	Closed	-$1.28M	–	1511
2024 Q4	$1.28M	Sell	56,327 -178,735	-76%	-$3.9M	0.01%	851
2024 Q3	$4.27M	Buy	+235,062	New	+$5.45M	0.02%	480
2024 Q2	–	Sell	-32,300	Closed	-$1.15M	–	1516
2024 Q1	$1.15M	Sell	32,300 -10,366	-24%	-$415K	﹤0.01%	847
2023 Q4	$1.86M	Sell	42,666 -9,282	-18%	-$365K	0.01%	684
2023 Q3	$1.98M	Sell	51,948 -53,569	-51%	-$2.25M	0.01%	627
2023 Q2	$4.34M	Buy	+105,517	New	+$5.08M	0.02%	429
2022 Q3	–	Sell	-4,916	Closed	-$266K	–	1172
2022 Q2	$266K	Buy	+4,916	New	+$295K	﹤0.01%	885

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IART Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Integra LifeSciences (IART) in Q1 2025, closing a stake of 56,327 shares — an estimated $1.28M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IART in Q2 2022 and held it in 7 quarters. The position peaked at $4.34M in Q2 2023. 219 funds tracked by Wall St. Rank hold IART as of Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Integra LifeSciences position as of Q1 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 56,327 Integra LifeSciences shares in Q1 2025, an estimated $1.28M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Integra LifeSciences in Q2 2022 and held it in 7 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Integra LifeSciences position peaked at $4.34M in Q2 2023.
219 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.